ALZN — Alzamend Neuro Income Statement
0.000.00%
Last trade - 00:00- $7.46m
- $3.51m
Annual income statement for Alzamend Neuro, fiscal year end - April 30th, USD millions except per share, conversion factor applied.
2021 April 30th | 2022 April 30th | 2023 April 30th | 2024 April 30th | 2025 April 30th | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 4.89 | 12.3 | 14.9 | 9.94 | 4.5 |
| Operating Profit | -4.89 | -12.3 | -14.9 | -9.94 | -4.5 |
| Total Net Non Operating Interest Income / Expense | |||||
| Net Income Before Taxes | -5.05 | -12.4 | -14.9 | -9.95 | -4.51 |
| Net Income After Taxes | -5.05 | -12.4 | -14.9 | -9.95 | -4.51 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -5.05 | -12.4 | -14.9 | -9.95 | -4.51 |
| Adjustments to Net Income | |||||
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -5.05 | -12.4 | -14.9 | -9.95 | -5.11 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -81.2 | -187 | -206 | -132 | -11.3 |